Navigation Links
New Analysis Shows Age has a Significant Effect on Outcomes in Patients Being Treated for Clostridium difficile Infection (CDI)
Date:2/14/2013

of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, possibly allowing C. difficile bacteria to flourish.

About DIFICID® (fidaxomicin) Tablets
DIFICID is the first macrolide antibacterial drug indicated for Clostridium difficile-associated diarrhea (CDAD) to be approved in over 25 years in the U.S.  It is indicated for the treatment of CDAD in adults 18 years of age or older. DIFICID is administered in 200 milligram tablets given orally twice daily.

Important Safety Information for DIFICID
DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin or to any of the excipients in the formulation. DIFICID should not be used for systemic infections. Only use DIFICID for infection proven or strongly suspected to be caused by C. difficile. Prescribing DIFICID in the absence of a proven or strongly suspected C. difficile infection is unlikely to provide benefit to the patient and increases the risk of the development of drug resistant bacteria. The most common adverse reactions are nausea (11%), vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia (2%) and neutropenia (2%).

About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society.  Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved macrolide antibacterial drug for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older and is commercializing DIFICID in the U.S. and Canada.  Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™.
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
2. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
3. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
4. Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
5. Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
6. Negative Pressure Wound Therapy (NPWT) - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
7. Demand for Product Pipeline Review and Analysis Rises in the Global Pharma Industry
8. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
9. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
10. Clinical Chemistry Market Report & Forecast (2012 - 2015): Global Analysis
11. Medical Diagnostic & Therapeutic Ultrasound Devices Market (2012 - 2017) - Global Trends & Competitive Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2014 Reportlinker.com announces that a new ... Asia-Pacific Infusion Therapy Device Market ... Abstract: The Asia-Pacific ... infusion pumps, syringe infusion pumps, disposable infusion pumps, ... categories are segmented based on the type of ...
(Date:9/2/2014)... The Pharmaceutical Care Management Association (PCMA), the national association ... lawsuit in Iowa federal court ... law that restricts tools used by PBMs to lower ... The law—HF 2297—forces PBMs to overpay ... Maximum Allowable Cost (MAC) lists that keep generic drug ...
(Date:9/2/2014)... NEW YORK , Sept. 2, 2014 /PRNewswire/ ... report is available in its catalogue: ... 2014 http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... H2, 2014 Summary GlobalData,s clinical ... Review, H2, 2014" provides data on the Acute ...
Breaking Medicine Technology:Asia-Pacific Infusion Therapy Device Market 2Asia-Pacific Infusion Therapy Device Market 3Asia-Pacific Infusion Therapy Device Market 4Asia-Pacific Infusion Therapy Device Market 5Asia-Pacific Infusion Therapy Device Market 6Asia-Pacific Infusion Therapy Device Market 7Asia-Pacific Infusion Therapy Device Market 8Asia-Pacific Infusion Therapy Device Market 9Asia-Pacific Infusion Therapy Device Market 10Asia-Pacific Infusion Therapy Device Market 11Asia-Pacific Infusion Therapy Device Market 12Asia-Pacific Infusion Therapy Device Market 13Asia-Pacific Infusion Therapy Device Market 14Lawsuit Challenges Iowa Health Mandate that Forces Employers to Pay More for Prescription Drugs 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... Oct. 20 Premier Research Group Limited, the international ... of Bernard Sweeney as Executive Director, Medical Devices. In ... in the operations, strategic planning, and corporate development of ... will be based in Premier Research,s Swiss office. , ...
... 20 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... Investor Conference at 11:30 a.m. Pacific Time on October ... San Diego, California. , ISTA,s Chief Financial Officer, Lauren ... and clinical progress. To access the live audio broadcast, ...
Cached Medicine Technology:Premier Research Names Bernard Sweeney as Executive Director, Medical Devices 2
(Date:9/2/2014)... Germany, September 2, 2014 In a large ... researchers found that mild cognitive impairment (MCI) occurred ... mellitus type 2. Interestingly, this strong association was ... in older participants (66-80 years) the association vanished. ... of Alzheimer,s Disease . , The concept of ...
(Date:9/2/2014)... Melbourne, Australia (PRWEB) September 03, 2014 ... Australia attend to millions of people annually, arranging care ... subdivision's not-for-profit and private enterprises are expected to derive ... government funding, donations and private income. Over the five ... at an annualised rate of 6.6%, including growth of ...
(Date:9/2/2014)... Steven Reinberg HealthDay ... A device intended to help with weight loss by blocking ... meet expectations in a trial among obese patients. Using ... the brain and stomach, researchers hoped to suppress feelings of ... anticipated. "A device that safely blocks the nerve that ...
(Date:9/2/2014)... Doctors trained in locations with less intensive (and expensive) ... clinical decisions that spare patients unnecessary and excessive medical ... Internal Medicine . , "Growing concern about the costs ... assessing physicians, ability to avoid the provision of unnecessary ... Outcomes Group and The Dartmouth Institute for Health ...
(Date:9/2/2014)... Last year, SIGVARIS took graduated ... of a luxurious line of graduated compression socks with natural ... COTTON Socks are joining the SIGVARIS MEDICAL collection for those ... comfort of natural cotton fibers. , “When people step ... find socks as soft as the finest cashmere,” says Clay ...
Breaking Medicine News(10 mins):Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2
... a few millimeters, depends on a supply of nutrients ... vascular wall cells of neighboring blood vessels to sprout ... blood circulation. , This process called angiogenesis involves ... receptors on the vascular wall cells. The departments of ...
... birds in the tropics look like they,re a drag to ... experiments by University of California, Berkeley, biologists shows that they ... at least in hummingbirds. , "We estimate that having a ... to 3 percent, which means the bird has to visit ...
... will help 5,000 more impoverished children in ... 2009 Best Picture "Slumdog Millionaire" shines the ... in India. Children International answers ... center to help poor children in Calcutta.To ...
... RALEIGH, N.C., March 12 MedThink Communications, a ... doctorate-level associate scientific director to support its rapidly ... two scientific directors at MedThink who provide high-level ... clients. With a team of seven doctorate-level medical ...
... study finds , , THURSDAY, March 12 (HealthDay News) ... testing athletes, because current tests ignore important ethnic ... and other hormones that increase testosterone levels are ... used in sports, according to the World Anti-Doping ...
... Highlights- Revenue: $35.7 million, up 19% from $29.9 million ... Q4,07LAWRENCE, Mass., March 12 NxStage Medical, Inc. (Nasdaq: ... dialysis products, today reported financial results for the three ... included revenue and Adjusted EBITDA results above the top ...
Cached Medicine News:Health News:A new measure for the malignancy of melanoma 2Health News:Long, sexy tails not a drag on male birds 2Health News:Long, sexy tails not a drag on male birds 3Health News:Long, sexy tails not a drag on male birds 4Health News:Photos: Children International Opens Center to Help Poor Children in India 2Health News:MedThink Hires Associate Scientific Director to Support Its Growing Health Care Clientele 2Health News:European Researchers Call for New Doping Standards 2Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 9Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 10Health News:NxStage Reports Fourth Quarter and Full Year 2008 Financial Results 11
Polyester ribbons (3) impregnated with different OD values of conjugated Protein A...
Polyester ribbon impregnated with conjugated Protein A - .13 OD per sq. cm....
Polyester ribbon impregnated with conjugated Protein A - .25 OD per sq. cm....
Colloidal Gold Conjugated, Protein A - 12 OD...
Medicine Products: